187 related articles for article (PubMed ID: 714324)
1. Oral contraceptive estrogen and plasma lipid levels.
Hedlin A; Kuksis A; Geher K
Obstet Gynecol; 1978 Oct; 52(4):430-5. PubMed ID: 714324
[TBL] [Abstract][Full Text] [Related]
2. Metabolic effects of oral contraceptives containing 30 micrograms and 50 micrograms of oestrogen.
Nash AL; Cornish EJ; Hain R
Med J Aust; 1979 Sep; 2(6):277-81. PubMed ID: 230411
[TBL] [Abstract][Full Text] [Related]
3. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC
Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353
[TBL] [Abstract][Full Text] [Related]
4. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
5. [Changes in plasma lipids caused by oral contraceptives].
Kaffarnik H
Z Ernahrungswiss Suppl; 1972; 12():Suppl 12:67-72. PubMed ID: 4114609
[No Abstract] [Full Text] [Related]
6. Effects of oral contraceptives on lipoprotein lipids: a prospective study.
Powell MG; Hedlin AM; Cerskus I; Kakis G; Prudham D; Rosenrot P
Obstet Gynecol; 1984 Jun; 63(6):764-70. PubMed ID: 6427714
[TBL] [Abstract][Full Text] [Related]
7. Oestrogen containing oral contraceptives and antithrombin III activity.
Rákóczi I; Nagy I; Szigetvári I; Losonczy H; Hadnagy J; Gáti I
Acta Physiol Acad Sci Hung; 1974; 45(3-4):281-6. PubMed ID: 4471272
[TBL] [Abstract][Full Text] [Related]
8. Effects on blood lipid and androgen levels of two triphasic oral contraceptives.
Janaud A; Rouffy J; Upmalis D; Dain MP
Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():114-6. PubMed ID: 8260968
[No Abstract] [Full Text] [Related]
9. A randomized prospective study of the metabolic effects of four low-estrogen oral contraceptives.
Briggs MH
J Reprod Med; 1983 Jan; 28(1 Suppl):92-9. PubMed ID: 6403706
[TBL] [Abstract][Full Text] [Related]
10. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene.
Lepot MR; Gaspard UJ
Int J Fertil; 1987; 32 Suppl():15-20. PubMed ID: 2906343
[TBL] [Abstract][Full Text] [Related]
11. Long-term profile of a new progestin.
Lippman J
Int J Fertil; 1992; 37 Suppl 4():218-22. PubMed ID: 1362189
[TBL] [Abstract][Full Text] [Related]
12. [Long-term effect of hormonal contraceptives on the behavior of serum lipids].
Klinger G; Carol W; Hoppe H; Müller B; Bonow A
Zentralbl Gynakol; 1977; 99(5):271-6. PubMed ID: 194435
[TBL] [Abstract][Full Text] [Related]
13. Hemostatic system changes induced by 50 micrograms and 30 micrograms estrogen/progestogen oral contraceptives. Modification of estrogen effects by levonorgestrel.
Sabra A; Bonnar J
J Reprod Med; 1983 Jan; 28(1 Suppl):85-91. PubMed ID: 6834350
[TBL] [Abstract][Full Text] [Related]
14. The effect of oral contraceptives on mononuclear cell cholesteryl ester hydrolase activity.
Hagemenas FC; Yatsu FM; Manaugh LC
Lipids; 1980 Jan; 15(1):39-44. PubMed ID: 7360009
[TBL] [Abstract][Full Text] [Related]
15. Plasma lipid and lipoprotein alterations during oral contraceptive administration.
Sachs BA; Wolfman L; Herzig N
Obstet Gynecol; 1969 Oct; 34(4):530-5. PubMed ID: 5822679
[No Abstract] [Full Text] [Related]
16. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
[TBL] [Abstract][Full Text] [Related]
17. Effect of synthetic oestrogens and progestagens in oral contraceptives on bile lipid composition.
Down RH; Whiting MJ; Watts JM; Jones W
Gut; 1983 Mar; 24(3):253-9. PubMed ID: 6826111
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral: effects of oral contraceptives, pregnancy, and lactation.
Goldsmith NF; Johnston JO
J Bone Joint Surg Am; 1975 Jul; 57(5):657-68. PubMed ID: 1150709
[TBL] [Abstract][Full Text] [Related]
19. Body weight change during use of a monophasic oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene with a comparison of the women who completed versus those who prematurely discontinued intake.
Endrikat J; Gerlinger C; Cronin M; Wessel J; Ruebig A; Rosenbaum P; Düsterberg B
Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):199-204. PubMed ID: 11848649
[TBL] [Abstract][Full Text] [Related]
20. [Influence of cyclic Ovosiston therapy on plasma lipid fractions of free cholesterol, total cholesterol and phospholipid].
Carol W; Hempel E; Klinger G; Bünnig S
Endokrinologie; 1970; 57(1):108-14. PubMed ID: 4099595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
